OMRF researchers uncover a genetic link between lymphatic valve formation and Crohn's disease, paving the way for future treatments.

A two-decade study finds notable differences in disease course and outcomes between ileal and colonic paediatric-onset ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

Crohn’s is a type of inflammatory bowel disease. Some people with this condition use these nutrition replacements as their exclusive diet for a period of 4–12 weeks.

The most popular TikTok videos related to inflammatory bowel disease (IBD) have millions of views – but very low scores for quality of ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab (Omvoh) for adults with moderately to severely active Crohn’s disease who have not ...

Crohn’s Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review. Life (Basel, Switzerland), 13 (10), 2062. https ...

ALBUQUERQUE, N.M. — Crohn's disease is a serious long-term condition affecting hundreds of thousands of people in this country and gets a lot of attention at the University of New Mexico Hospital.

Remember that Crohn’s disease varies greatly from person to person. Some people experience mild symptoms with long periods of remission, while others have more frequent flares with severe symptoms.

PRINCE GEORGE—Wynne Fitzpatrick a first-year nursing baccalaureate student at CNC has just received a $5,000 national scholarship from Crohn’s and Colitis Canada for her academic achievements and ...

Most people associate Crohn’s disease with abdominal pain, diarrhea, and weight loss. While these symptoms are common, the condition’s effects extend far beyond the digestive system.

1. FDA approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease. Press release. Eli Lilly and Company. January 15, 2024.